<![CDATA[Debating CAR T-Cell Therapy Vs Bispecifics at First Relapse in Myeloma]]>

ConferenceCAR T-Cell TherapyBispecific antibodiesNeutral

AI Analysis

Summary

Experts at the 2026 SOHO Annual Meeting debated the optimal treatment sequence of CAR T-cell therapy versus bispecific antibodies in patients with relapsed/refractory multiple myeloma at first relapse.

Importance:3/10

Sentiment:

0.00

myelomaCAR T-cellbispecific antibodiesrelapsed/refractorySOHO 2026

Related Companies

$TRAX

Read the original article

Published by Cancer Network on September 12, 2026 4:00 PM

Read Original